Research Article
A Novel Herbal Medicine for Dyslipidemia: Assessments in Experimental Models
Table 2
Effect of GANMO on lipid levels in cholesterol-induced dyslipidemia after 2 weeks of treatment.
| Groups/treatment 2nd week | n | TG ( ± SD) | TC ( ± SD) | HDL-C ( ± SD) | LDL-C ( ± SD) |
| Control group | 10 | 0.50 ± 0.11 | 2.16 ± 0.15 | 1.08 ± 0.15 | 0.85 ± 0.22 | Model group | 10 | 0.54 ± 0.17 | 2.38 ± 0.35 | 1.16 ± 0.20 | 1.11 ± 0.19 | Atorvastatin (10 mg/kg) | 10 | 0.49 ± 0.12 | 2.36 ± 0.29 | 1.06 ± 0.16 | 1.08 ± 0.34 | GANMO (15.1 g/kg) | 10 | 0.74 ± 0.25 | 2.66 ± 0.28 | 1.05 ± 0.22 | 1.27 ± 0.46 | GANMO (45.3 g/kg) | 10 | 0.45 ± 0.14 | 2.56 ± 0.33 | 0.99 ± 0.17 | 1.37 ± 0.40 |
|
|